COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA
    1.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA 审中-公开
    用于治疗流感的组合治疗

    公开(公告)号:US20090298797A1

    公开(公告)日:2009-12-03

    申请号:US12469319

    申请日:2009-05-20

    摘要: Compositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject.

    摘要翻译: 提供用于治疗一种或多种流行性感冒症状的组合物和方法,优选因感染甲型流感(H5N1)感染流感。 已经发现,与单独施用神经氨酸酶抑制剂相比,神经氨酸酶抑制剂与两种免疫调节剂的组合的施用增加了感染后24,48或甚至72小时的受试者的存活率。 优选的神经氨酸酶抑制剂是扎那米韦。 优选的免疫调节剂包括但不限于塞来昔布和美沙拉嗪。 另一个实施方案提供了一种治疗流行性感冒的方法,优选地,由于禽流感A(H5N1)的感染,通过对感染了流感病毒的受试者施用有效量的神经氨酸酶抑制剂来抑制或减少感染的流感病毒的出芽 受试者的细胞和有效量的至少两种有效减少或抑制受试者中一种或多种炎症症状的免疫调节剂。